Pharma

Your Article Summary

See Latest Articles

Cytokinetics Presents Phase IIa Clinical Trials Data Relating to Omecamtiv Mecarbil at the European Society of Cardiology Congress 2009
Cytokinetics, 09/01/09

Cytokinetics, Incorporated announced that data from two Phase IIa clinical trials evaluating omecamtiv mecarbil, one in stable heart failure patients and one in patients with ischemic cardiomyopathy and angina, were presented at the European Society of Cardiology Congress 2009 in Barcelona, Spain. The company believes these data provide support for the further clinical development of this novel drug candidate as a potential treatment for heart failure.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Sanofi Pasteur expands study of vaccine against Clostridium difficile into the U.S.
Sanofi-aventis, 12/16/09

A Clinical Review of Echinocandins in Pediatric Patients
Annals of Pharmacotherapy, 12/16/09

Second Pivotal Phase III Study of Gileads Darusentan for Resistant Hypertension Misses Primary Endpoints
Gilead, 12/15/09

 See all of Drug Trials

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

AstraZeneca and the University of Virginia sign strategic research collaboration to develop novel treatments for cardiovascular disease
AstraZeneca, 12/16/09

Sanofi Pasteur expands study of vaccine against Clostridium difficile into the U.S.
Sanofi-aventis, 12/16/09

Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study
Amylin Pharmaceuticals, 12/16/09

 See all of Research & Development